In addition, the results of immune cell markers also showed that PTC patients with a high tumor stage, lymph node metastasis, and a larger tumor size had an increased number of immune cells, and the increase in tumor-promoting immune cells was particularly significant, including TPSAB1 (MCs), FOXP3 (Tregs), CD1A (iDCs), and neutrophils (CXCR2s) (Figures S1B–D). This evidence concerns the gene FOXP3 and neoplasm.